Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis
Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blinded placebo controlled trial to assess the
benefit of sulfasalazine in the treatment of PSC. The specific objectives of this study are
to determine if sulfasalazine treatment 1) results in reduced serum ALP and other biomarkers
of liver injury in PSC; 2) improves PSC patient symptoms; and 3) is safe in patients with
PSC.